Agitation and aggression in people with Alzheimer's disease

Current Opinion in Psychiatry

Volumn 26, Issue 3, 2013, Pages 252-259

  Ballard, Clive ^a   Corbett, Anne ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

aggression; agitation; Alzheimer's disease; dementia; treatment

Indexed keywords

ARIPIPRAZOLE; CARBAMAZEPINE; CITALOPRAM; DONEPEZIL; DROPERIDOL; HALOPERIDOL; MEMANTINE; OLANZAPINE; PLACEBO; PRAZOSIN; PROMAZINE; QUETIAPINE; RISPERIDONE; RIVASTIGMINE; SERTRALINE; THIORIDAZINE;

AGGRESSION; AGITATION; ALZHEIMER DISEASE; BEHAVIORAL PATHOLOGY IN ALZHEIMER DISEASE RATING SCALE; CLINICAL PRACTICE; COGNITIVE DEFECT; COGNITIVE THERAPY; COHEN MANSFIELD AGITATION INVENTORY; DYSPHORIA; DYSTONIA; HEALTH PRACTITIONER; HUMAN; MEDICAL SOCIETY; META ANALYSIS (TOPIC); NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PARKINSONISM; POST HOC ANALYSIS; PRESCRIPTION; PSYCHOPHARMACOTHERAPY; PSYCHOSOCIAL CARE; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEDATION; TARDIVE DYSKINESIA;

AGGRESSION; ALZHEIMER DISEASE; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; EVIDENCE-BASED MEDICINE; HUMANS; PSYCHOMOTOR AGITATION; PSYCHOTHERAPY;

EID: 84875859346     PISSN: 09517367     EISSN: 14736578     Source Type: Journal    
DOI: 10.1097/YCO.0b013e32835f414b     Document Type: Review

References (55)

1. Alzheimer's Disease International Fact Sheet: the prevalence of dementia worldwide. December 2008. www.alz.co.uk/adi/pdf/prevalence.pdf. [Accessed 4 January 2013]
2. Lyketsos CG, Lopez O, Jones B, et al. Mental and behavioral disturbances in dementia: findings from the Cache County Study on Memory in Aging. Am J Psych 2000; 157:708-714. (Pubitemid 30249648)
3. Margallo-Lana M, Swann A, O'Brien J, et al. Prevalence and pharmacological management of behavioural and psychological symptoms amongst dementia sufferers living in care environments. Int J Geriatr Psychiatry 2001; 16:39-44. (Pubitemid 32111815)
4. Lyketsos CG. Neuropsychiatric symptoms (behavioral and psychological symptoms of dementia) and the development of dementia treatments. Int Psychogeriatr 2007; 19:409-420. (Pubitemid 46707421)
5. Gilley DW, Whalen ME, Wilson RS, et al. Hallucinations and associated factors in Alzheimer's disease. J Neuropsych Clin Neurosci 1991; 3:371-376.
6. Rabins PV, Mace NL, Lucas MJ, et al. The impact of dementia on the family. JAMA 1982; 248:333-335. (Pubitemid 12070768)
7. Ballard CG, EastwoodC, GahirM, Wicock G. A followup study of depression in the carers of dementia sufferers. BMJ 1996; 312:947. (Pubitemid 26111786)
8. Banerjee S, Smith SC, Lamping DL, et al. Quality of life in dementia: more than just cognition. An analysis of associations with quality of life in dementia. J Neurol Neurosurg Psych 2006; 77:146-148. (Pubitemid 43220831)
9. Steele C, Rovner B, Chase GA, FolsteinM.Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease. Am J Psych 1990; 147:1049-1051. (Pubitemid 20257519)
10. Cohen-Mansfield J, Lipson S. The utility of pain assessment for analgesic use in persons with dementia. Pain 2008; 134:16-23. (Pubitemid 350251001)
11. Lyketsos CG, Colenda CC, Beck C, et al. Position statement of the American Association for Geriatric Psychiatry regarding principles of care for patients with dementia due to Alzheimer disease. Am J Geriatr Psychiatry 2006; 14:561-572. (Pubitemid 44036480)
12. Cohen-Mansfield J, Libin A, Marx MS. Nonpharmacological treatment of agitation: a controlled trial of systematic individualized intervention. J Gerontol A Biol Sci Med Sci 2007; 62:908-916. (Pubitemid 350139005)
13. Cohen-Mansfield J, Werner P. Management of verbally disruptive behaviors in nursing home residents. J Gerontol Series A-Biol Sci Med Sci 1997; 52:369-377.
14. Gitlin LN, Winter L, Burke J, et al. Tailored activities to manage neuro-psychiatric behaviors in persons with dementia and reduce caregiver burden: a randomized pilot study. Am J Geriatr Psychiatry 2008; 16:229-239.
15. Ballard C, Brown R, Fossey J, et al. Brief psychosocial therapy for the treatment of agitation in Alzheimer disease (The CALM-AD Trial). Am J Geriatr Psychiatry 2009; 17:726-733.
16. Bird M. Psychosocial approaches to challenging behavior in dementia: a controlled trial. Report to the Commonwealth Department of Health and Ageing. Office for Older Australians: Canberra; 2002.
17. Fossey J, Ballard C, Juszczak E, et al. Effect of enhanced psychosocial care on antipsychotic use in nursing home residents with severe dementia: cluster randomized trial. BMJ 2006; 332:756-758. (Pubitemid 44365651)
18. Ballard C, Powell I, James I, et al. Can psychiatric liaison reduce neuroleptic use and reduce health service utilization for dementia patients residing in care facilities. Int J Geriatric Psychiatry 2002; 17:140-145. (Pubitemid 34130304)
19. Chenoweth L, King MT, Jeon YH, et al. Caring for Aged Dementia Care Resident Study (CADRES) of person-centred care, dementia-care mapping, and usual care in dementia: a cluster-randomised trial. Lancet Neurol 2009; 8:317-325.
20. Schneider LS, Pollock VE, Lyness SA. A metaanalysis of controlled trials of neuroleptic treatment in dementia. J Am Geriatr Soc 1990; 38:553-563. (Pubitemid 20177819)
21. Lonergan E, Luxenberg J, Colford J, et al. Haloperidol for agitation in dementia. Cochrane Database Syst Rev 2005(4).
22. Tune LE, Steele C, Cooper T. Neuroleptic drugs in the management of behavioral symptoms of Alzheimer's disease. Psychiatr Clin North Am 1991; 14:353-373.
23. Reilly JG, Ayis SA, Ferrier IN, et al. QTc-interval abnormalities and psycho-tropic drug therapy in psychiatric patients. Lancet 2000; 355:1048-1052. (Pubitemid 30162807)
24. Ballard C, Howard R. Neuroleptic drugs in dementia: benefits and harm. Nat Rev Neurosci 2006; 7:492-500. (Pubitemid 44012289)
25. Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry 2006; 14:191-210.
26. Schneider LS, Tariot PN, Dagerman KS, et al. CATIE-AD Study Group. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med 2006; 355:1525-1538 (Pubitemid 44547805)
27. Deaths with antipsychotics in elderly patients with behavioral disturbances. U.S. Food and Drug Administration, FDA Public Health Advisory, Centre for Drug Evaluation and Research. FDA; 13 July 2005.
28. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 2005; 294:1934-1943. (Pubitemid 41464695)
29. Ballard C, Hanney ML, Theodoulou M, et al. DART-AD investigators. The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial. Lancet Neurol 2009; 8:151-157.
30. Wang PS, Schneeweiss S, Avorn J, et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med 2005; 353:2335-2341. (Pubitemid 41713745)
31. Ballard C, Creese B, Corbett A, et al. Atypical antipsychotics for the treatment of behavioral and psychological symptoms in dementia, with a particular focus on longer term outcomes and mortality. Expert Opin Drug Saf 2011; 10:35-43.
32. Angelucci F, Bernadini S, Gravina P, et al. Delusion symptoms and response to antipsychotic treatment are associated with the 5-HT2A receptor polymorphism (102T/C) in Alzheimer's disease: a 3-year follow-up longitudinal study. J Alzheimers Dis 2009; 17:203-211.
33. Dombrovski AY, Mulsant BH, Ferrell RE, et al. Serotonin transporter triallelic genotype and response to citalopram and risperidone in dementia with behavioral symptoms. Int Clin Psychopharmacol 2010; 25:37-45.
34. Husebo B, Ballard C, Sandvik R, et al. Efficacy of treating pain to reduce behavioural disturbances in residents of nursing homes with dementia: cluster randomised clinical trial. BMJ 2011; 343:4065.
35. Trinh NH, Hoblyn J, Mohanty S, et al. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis. JAMA 2003; 289:210-216. (Pubitemid 36068709)
36. Holmes C, Wilkinson D, Dean C, et al. The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease. Neurology 2004; 63:214-219. (Pubitemid 38971117)
37. Ballard C, Margallo-Lana M, Juszczak E, et al. Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial. BMJ 2005; 330:874-877. (Pubitemid 40545686)
38. Howard RJ, Juszczak E, Ballard C, et al. Donepezil for the treatment of agitation in Alzheimer's disease. N Engl J Med 2007; 357:1382-1392. (Pubitemid 47535593)
39. Tariot PN, Solomon PR, Morris JC, et al. A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology 2000; 54:2269-2276.
40. Gauthier S, Feldman H, Hecker J, et al. Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease. Int Psychogeriatr 2002; 14:389-404. (Pubitemid 36331605)
41. Gauthier S, Wirth Y, Mobius HJ. Effects of memantine on behavioural symptoms in Alzheimer's disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies. Int J Geriatr Psychiatry 2005; 20:459-464. (Pubitemid 40716339)
42. McShane R, Areosa Sastre A, Minakaran N. Memantine for dementia. Cochrane Database Syst Rev Issue 2. 2006. Art. No: CD003154.
43. Gauthier S, Loft H, Cummings J. Improvement in behavioural symptoms in patients with moderate to severe Alzheimer's disease by memantine: a pooled data analysis. Int J Geriatr Psychiatry 2008; 23:537-545. (Pubitemid 351722115)
44. Wilcock GK, Ballard CG, Cooper JA, et al. Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies. J Clin Psychiatry 2008; 69:341-348. (Pubitemid 351549385)
45. Fox C, Crugel M, Maidment I, et al. Efficacy of memantine for agitation in Alzheimer's dementia: a randomised double-blind placebo controlled trial. PLoS One 2012; 7:e35185.
46. Howard R, McShane R, Lindesay J, et al. Donepezil and memantine for moderate-to-severe Alzheimer's disease. N Engl J Med 2012; 366:893-903.
47. Pollock BG, Mulsant BH, Rosen J, et al. Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients. Am J Psychiatry 2002; 159:460-465. (Pubitemid 34184743)
48. Pollock BG, Mulsant BH, Rosen J, et al. A doubleblind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia. AmJ Geriatr Psychiatry 2007; 15:942-952.
49. Finkel SI, Mintzer JE, Dysken M, et al. A randomized, placebo-controlled study of the efficacy and safety of sertraline in the treatment of the behavioral manifestations of Alzheimer's disease in outpatients treated with donepezil. Int J Geriatr Psychiatry 2004; 19:9-18. (Pubitemid 38180687)
50. Teri L, Logsdon RG, Peskind E, et al. Treatment of agitation in AD: a randomized, placebo-controlled clinical trial. Neurology 2000; 55:1271-1278.
51. Tariot PN, Erb R, Podgorski CA, et al. Efficacy and tolerability of carbamazepine for agitation and aggression in dementia. Am J Psychiatry 1998; 155:54-61. (Pubitemid 28037549)
52. Olin JT, Fox LS, Pawluczyk S, et al. A pilot randomized trial of carbamazepine for behavioral symptoms in treatment-resistant outpatients with Alzheimer disease. Am J Geriatr Psychiatry 2001; 9:400-405. (Pubitemid 33015127)
53. Konovalov S, Muralee S, Tampi RR. Anticonvulsants for the treatment of behavioral and psychological symptoms of dementia: a literature review. Int Psychogeriatr 2008; 20:293-308. (Pubitemid 351230232)
54. Sharp SI, Ballard CG, Chen CP, et al. Aggressive behavior and neuroleptic medication are associated with increased number of alpha1-adrenoceptors in patients with Alzheimer disease. Am J Geriatr Psychiatry 2007; 15:435-437.
55. Wang LY, Shofer JB, Rohde K, et al. Prazosin for the treatment of behavioral symptoms in patients with Alzheimer disease with agitation and aggression. Am J Geriatr Psychiatry 2009; 17:744-751.